RxDoctor Payments DataLook up a doctor →

Brian Betensky, MD

Clinical Cardiac Electrophysiology · Sarasota, FLNPI 1851553481

Payments from drug & device makers

$616,281in general payments, 2019–2025

Across 1,017 payments — averaging $605.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$298K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$114K
  • Elutia, Inc.$74K
  • Medical Device Business Services, Inc.$57K
  • Abbott$35K
  • Biosense Webster, Inc.$27K
  • plus $11K from 25 others

What the payments were for

  • Consulting fees$130,62432%
  • Speaking & faculty fees$259,63463%
  • Travel & lodging$4,6211%
  • Food & beverage$16,6154%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$616,281 in reported general payments places this provider in the 90th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$1,722,785
Medicare patients
2,643
Services billed
11,604

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban626$781,748
FarxigaDapagliflozin Propanediol65$74,926
XareltoRivaroxaban63$68,460
EntrestoSacubitril/Valsartan51$61,107
MultaqDronedarone Hcl29$50,791
Repatha SureclickEvolocumab36$24,532
Dofetilide25$11,313
Metoprolol Succinate534$8,039
Flecainide Acetate136$5,979
Mexiletine Hcl43$4,192
SotalolSotalol Hcl180$3,825
Amiodarone Hcl59$3,443
Ezetimibe49$1,667
Atorvastatin Calcium142$1,427
Metoprolol Tartrate193$1,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$244$781,748626 claims
AstraZenecaFarxiga$35$74,92665 claims
Johnson & JohnsonXarelto$1,315$68,46063 claims
NovartisEntresto$524$61,10751 claims
Sanofi-aventis U.S. LLCMultaq$326$50,79129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →